Rigel Investor/Analyst DayRigel plans to host an investor/analyst day on October 13, 2011 in New York City to present its product development pipeline with a focus on R343, Rigel's inhaled syk inhibitor for asthma. At this event, members of Rigel's management team will present the Phase 1 allergen challenge data for R343 in mild asthmatics as well as the proposed design for the Phase 2 clinical trial for R343 in asthma that is expected to commence in the first half of 2012.
About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its Phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma.
This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's expectations as to its year-end cash position and the sufficiency of its cash, cash equivalents and available-for-sale securities; identification of a novel programs for clinical development, the potential indications for treatment, and the timing design, commencement and completion of clinical trials; and the timing of filing a new d
|SOURCE Rigel Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved